

NOV 23 2007

(Use as many sheets as necessary)

Sheet 1 of 1

Attorney Docket No. ABB10010P02440US

Examiner Initials*	Cite No. <sup>1</sup>	U.S. Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear
		Number Kind Code <sup>2</sup> (if known)			
		US-			

Examiner Initials <sup>a</sup>	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>2</sup> -Number <sup>3</sup> -Kind Code <sup>4</sup> (if known)				
		WO 2004/067561	08/12/2004	Abbott GMBH & Co. KG		
		WO 2001/010900	02/15/2001	Univ. of Southern California; Northwestern University		
		WO 1998/033815	08/06/1998	Acumen Pharmaceuticals, Inc.		
Examiner Signature				Date Considered		

Examiner Initials*	Cite No.†	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>‡</sup>
		International Society for Neurochemistry, <i>J. Neurochem. Journal of Neurochemistry</i> , 2005, 95, 834-847, Barghorn et al., Globular Amyloid $\beta$ -peptide <sub>1-42</sub> Oligomer - A Homogenous and Stable Neuropathological Protein in Alzheimer's Disease	
		The American Society for Biochemistry and Molecular Biology, Inc. <i>The Journal of Biological Chemistry</i> Vol. 278, No. 13, Issue of March 28, pp. 11612-11622, 2003, 2003, Stine et al., In Vitro Characterization of Conditions for Amyloid- $\beta$ Peptide Oligomerization and Fibrillogenesis	
		Federation of European Neuroscience Societies. <i>European Journal of Neuroscience</i> , Vol. 13, pp 2015-2024, 2001, Demeester et al., Comparison of the Aggregation Properties, Secondary Structure and Apoptotic Effects of Wild-Type, Flemish and Dutch N-terminally Truncated Amyloid $\beta$ Peptides	
		The American Society for Biochemistry and Molecular Biology, Inc. <i>The Journal of Biological Chemistry</i> , Vol. 277, No. 35, Issue of August 30, pp 32046-32053, 2002, Dahlgren et al., Oligomeric and Fibrillar Species of Amyloid- $\beta$ Peptides Differently Affect Neuronal Viability	
		Proceedings of the National Academy of Sciences of USA, Vol. 100, January 7, 2003, pp. 330-335, No. 1, Bitan et al., Amyloid $\beta$ -protein (A $\beta$ ) Assembly: A $\beta$ 40 and A $\beta$ 42 Oligomerize Through Distinct Pathways	
		Elsevier Science Ltd., <i>J. Mol. Biol.</i> (2002) 319, pp. 1279-1290, Wurth et al., Mutations that Reduce Aggregation of the Alzheimer's A $\beta$ 42 Peptide: an Unbiased Search for the Sequence Determinants of A $\beta$ Amyloidogenesis	

\*EXAMINER: Initial if reference considered; whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kind Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04 <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standards ST 16, if possible. <sup>6</sup> Applicant is to place a checkmark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) and application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. If you are unable to provide this information, you may request a waiver of this requirement. If you are unable to provide this information, you may request a waiver of this burden should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, 2200 Rayburn Building, Washington, DC 20315-4400. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner For Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

THIS ADDRESS. SEND TO: Commissioner For Patents, P.O. Box 1450, Alexandria, VA 22313-1450